{"created":"2023-07-27T06:55:40.156419+00:00","id":51798,"links":{},"metadata":{"_buckets":{"deposit":"0fdabbee-9a1b-4cb1-bbb3-d006290212c0"},"_deposit":{"created_by":18,"id":"51798","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"51798"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00051798","sets":["2812:2813:4085"]},"author_link":["93268","93267"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-05-24","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"7p.","bibliographicVolumeNumber":"2018-04-01 - 2022-03-31","bibliographic_titles":[{"bibliographic_title":"令和3(2021)年度 科学研究費補助金 基盤研究(B) 研究成果報告書"},{"bibliographic_title":"2021 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Li, Yingyi"}],"nameIdentifiers":[{"nameIdentifier":"93268","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"70401940","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=70401940"}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Hepatitis B virus (HBV) infection is difficult to cure owing to the persistence of cccDNA. Here, we identified DOCK11, a guanine nucleotide exchange factor (GEF), as a candidate druggable target for HBV. Interestingly, DOCK11 functionally associated with retrograde trafficking proteins in trans-Golgi network (TGN), AGAP2 and ARF1 together with HBV capsid, to open an alternative retrograde trafficking route of HBV capsid from early endosomes (EEs) to the TGN and then to the endoplasmic reticulum (ER), thereby avoiding lysosomal degradation. cccDNA levels were strongly suppressed by shDOCK11. Surprisingly, combination of ETV plus shDOCK11 further reduced HBVDNA and cccDNA levels. Clinically, DOCK11 levels in the liver of patients with chronic hepatitis B were significantly reduced by entecavir treatment, and this reduction correlated with HBs antigen levels. Thus, DOCK11 could be a potential therapeutic target to prevent persistent HBV infection.","subitem_description_type":"Abstract"},{"subitem_description":"cccDNAは感染肝細胞核内にプールされるため，HBVを体内から完全に排除することが難しい。我々は単細胞遺伝子解析により，HBV複製の維持に係る遺伝子はDOCK11であることを明らかにした。DOCK11遺伝子の発現を抑制することにより，HBVの核内輸送が抑えられるだけでなく，細胞障害性も示されなかったため，DOCK11遺伝子発現を抑制する新薬の開発はB型肝炎の画期的な治療法になると期待したい。","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:18K07966, 研究期間(年度):2018-04-01 - 2022-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：「DOCK11ノックダウンによりcccDNA排除の新規抗HBV治療応用への基礎研究」研究成果報告書　課題番号18K07966\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07966/18K07966seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00058101","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=70401940"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=70401940","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K07966/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K07966/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07966/18K07966seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-18K07966/18K07966seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 影奕"}],"nameIdentifiers":[{"nameIdentifier":"93267","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"70401940","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=70401940"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-02-27"}],"displaytype":"detail","filename":"ME-PR-LI-Y-kaken 2022-7p.pdf","filesize":[{"value":"313.9 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-LI-Y-kaken 2022-7p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/51798/files/ME-PR-LI-Y-kaken 2022-7p.pdf"},"version_id":"2026e5f7-b2b7-4e49-a22f-0f38f9874413"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"DOCK11ノックダウンによりcccDNA排除の新規抗HBV治療応用への基礎研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"DOCK11ノックダウンによりcccDNA排除の新規抗HBV治療応用への基礎研究"},{"subitem_title":"Basic research on developing new anti-HBV therapeutic strategy for cccDNA elimination by DOCK11 knockdown in HBV infected hepatocytes","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["4085"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-02-27"},"publish_date":"2023-02-27","publish_status":"0","recid":"51798","relation_version_is_last":true,"title":["DOCK11ノックダウンによりcccDNA排除の新規抗HBV治療応用への基礎研究"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-07-01T05:18:22.518572+00:00"}